THAI ZUNG,ADAMKEWICZ JOANNE I.,SMITH VICTORIA,HAWKINS MICHAEL J.
申请号：
NZ62917813
公开号：
NZ629178A
申请日:
2013.02.28
申请国别(地区):
NZ
年份:
2016
代理人:
摘要：
Discloses the use of a pharmaceutical composition in the manufacture of a medicament for inhibiting matrix metalloproteinase 9 (MMP9) activity in a subject having an MMP9-associated disease or condition, wherein the pharmaceutical composition comprises a pharmaceutically acceptable excipient, and an antibody or antigen binding fragment thereof that binds to human MMP-9, wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable (VH) region comprising three complementarity determining regions (CDRs) as set forth in SEQ ID NOs: 13-15 and a light chain variable (VL) region comprising three CDRs as set forth in SEQ ID NOs: 16-18, wherein the composition is suitable for administration in an amount effective to inhibit MMP9 activity in the subject and the MMP9-associated disease or condition is rheumatoid arthritis, wherein the sequences are as defined in the complete specification. Also discloses related methods of detecting and monitoring diseases including cancer, autoimmune, inflammatory, or fibrotic diseases.
